Teva Pharmaceuticals USA, Inc

Teva Pharmaceuticals USA, Inc: 7 recalls listed since February 2026 across FDA.

By year

20267

By agency

FDA7

By category

Drug7

All recalls (7)

FDA•Sep 2, 2026MODERATE
traZODone Hydrochloride Tablets, USP, 50 mg
Teva recalls traZODone HCl 50 mg tablets due to foreign tablets/capsules in product.
FDA•May 5, 2026MODERATE
Octreotide Acetate for Injectable Suspension
Teva is recalling Octreotide Acetate 30 mg injection kits due to a lack of assurance of sterility.
2 products
FDA•Apr 17, 2026MODERATE
Claravis (isotretinoin capsule, USP) 10 mg
Teva is recalling Claravis 10 mg capsules (NDC 0555-1054-56, 0555-1054-86) due to out-of-specification Tretinoin impurity levels.
3 products
FDA•Apr 14, 2026MODERATE
Clonidine Transdermal System 0.2 mg/day
Teva recalls Clonidine Transdermal System 0.2 mg/day due to CGMP deviations (unapproved raw material).
3 products
FDA•Apr 8, 2026MODERATE
Isotretinoin Capsules, USP, 40 mg
Teva is recalling 40 mg Isotretinoin Capsules due to potency issues.
2 products
FDA•Mar 27, 2026MODERATE
Octreotide Acetate Injectable Suspension 20 mg
Teva recalls Octreotide Acetate 20 mg vials over sterility assurance concerns.
6 products
FDA•Feb 27, 2026MODERATE
Teva Pharmaceuticals: multiple tablets
Teva recalls Metoprolol Succinate ER tablets (25-200 mg) over failed dissolution specs.
4 products